Abeona therapeutics® reports second quarter 2025 financial results and corporate updates

- received fda approval for zevaskyn™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (rdeb) -
ABEO Ratings Summary
ABEO Quant Ranking